title: High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.
abstract: OBJECTIVE
  To estimate the range of poly(adenosine diphosphate [ADP]-ribose) polymerase expression in serous ovarian cancers and to determine whether expression is associated with response to therapy and outcome.
  
  
  METHODS
  Immunostaining for poly(ADP-ribose) polymerase was performed in 186 paraffin-embedded, serous ovarian cancers. Nuclear poly(ADP-ribose) polymerase expression was quantified using a scoring system that assesses both staining intensity and percentage of cells staining. Kaplan-Meier analysis was performed to evaluate the relationship between poly(ADP-ribose) polymerase expression and overall survival.
  
  
  RESULTS
  High poly(ADP-ribose) polymerase expression was present in 54% of serous cancers but was not associated with stage or grade. There was no difference in the rate of complete clinical response to primary chemotherapy between cases with low poly(ADP-ribose) polymerase expression (70%) compared with those with high poly(ADP-ribose) polymerase expression (71%). However, high poly(ADP-ribose) polymerase expression was associated with significantly worse median overall survival (36 compared with 43 months, P=.04, hazard ratio 0.71).
  
  
  CONCLUSIONS
  Expression of poly(ADP-ribose) polymerase in ovarian cancers is heterogeneous, and high expression in serous ovarian cancers is associated with worse overall survival. These data suggest that evaluation of poly(ADP-ribose) polymerase expression in the primary cancer could potentially allow selective use of poly(ADP-ribose) polymerase inhibitors in patients most likely to respond.
  
  
  METHODS
  III.
authors.affiliation: From the Department of Obstetrics and Gynecology/Division of Gynecologic Oncology and Department of Pathology, Duke University Medical Center, Durham, North Carolina; Department of Gynecology and Obstetrics, Kyoto University, Kyoto, Japan; and Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina.
authors.forename: Jason C
authors.initials: JC
authors.lastname: Barnett
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Bean
authors.forename: John M
authors.initials: JM
authors.lastname: Nakayama
authors.forename: Eiji
authors.initials: E
authors.lastname: Kondoh
authors.forename: Susan K
authors.initials: SK
authors.lastname: Murphy
authors.forename: Andrew
authors.initials: A
authors.lastname: Berchuck
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*; D011379:Prognosis; D055815:Young Adult
chemical_list: D011065:Poly(ADP-ribose) Polymerases